{"database": "lobbying", "table": "lobbying_activities", "rows": [[2600782, "6a80140a-417f-423f-a5cd-0469b2babcad", "Q1", "ELI LILLY AND COMPANY", 13392, "ELI LILLY AND COMPANY", 2021, "first_quarter", "CPT", "Prescription Drug Pricing Reduction Act (PDPRA - S.4199); Pharmaceutical intellectual property issues; Consolidated Appropriations Act 2021 (HR.133)", "Commerce, Dept of (DOC),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)", 0, 0, "2021-04-19T09:47:49.270000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2600782"], "units": {}, "query_ms": 0.3684459952637553, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}